Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

This study has been withdrawn prior to enrollment.
(slow accrual)
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT00119314
First received: July 12, 2005
Last updated: May 22, 2015
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: July 2005
  Primary Completion Date: July 2005 (Final data collection date for primary outcome measure)